management team

Robert Connelly has 27 years of experience in the life sciences sector including the last 16 years in serial entrepreneurial pursuits. Prior to joining Pulmatrix in January of 2008, Connelly was the CEO of Domantis, Ltd. before selling the company to Glaxo SmithKline for $454 million in cash, the largest valuation paid for a preclinical biotechnology company. Connelly joined Domantis in 2001 as the founding CEO and first employee. Domantis is a drug discovery company developing a pipeline of novel therapies based on the next generation of antibody molecules, fully human domain antibodies (dAbs). Connelly built Domantis into a 75 person organization with 15 therapeutic programs, seven partnerships, and over $80 million in private equity raised. Prior to Domantis Mr. Connelly spent six years with Bioveris, Inc. (formerly IGEN and since acquired by Roche) in the roles of Senior Vice President of Sales and Marketing and General Manager of IGEN's Life Sciences unit. In this capacity, Connelly took a central role in IGEN's financing activities and IPO, raising more than $150 million dollars during his tenure. Mr. Connelly spent the first 11 years of his career with Abbott Laboratories in sales, marketing, and management positions.

Dr. Hanrahan joins Pulmatrix from Sepracor where he most recently served as Executive Medical Director for Pulmonary Clinical Research. During his six years at Sepracor, he led clinical development activities for the asthma drug Levalbuterol and the COPD drug Arformoterol, through FDA approvals in 2005 and 2006, respectively. At Sepracor, Dr. Hanrahan led the worldwide clinical development of the entire portfolio of projects for pulmonary and internal medicine indications, and served on the Respiratory and Internal Medicine Therapeutic Assessment teams in support of partnering and M&A activities. Prior to joining Sepracor, he held multiple leadership positions spanning clinical development and medical affairs at Boehringer-Ingelheim and Muro Pharmaceuticals. Dr. Hanrahan began his career at Harvard Medical School as a faculty member in pulmonary and emergency medicine and researcher in pulmonary epidemiology, while holding corresponding hospital appointments at the Beth Israel Deaconess Medical Center. He was previously an Epidemic Intelligence Service Officer with the National Centers for Disease Control.

Eva Jack joined Pulmatrix from MedImmune LLC, the worldwide biologics unit of AstraZeneca PLC. Her most recent position was managing director, MedImmune Ventures where she was responsible for making and managing investments in private biotechnology companies. Prior to MedImmune Ventures, she was in MedImmune’s Business Development group. In this role, she was responsible for in-licensing, out-licensing and research collaborations with universities, medical research institutions, governments and companies.

Prior to joining MedImmune in 2004, Ms. Jack held a variety of positions at Intel Corporation. In her last position at Intel, she worked for Intel Capital, the company’s venture fund, and was responsible for investments and research collaborations in biotechnology and health care.

Ms. Jack holds a bachelor’s degree from the University of Virginia and a master’s degree in health sciences from The Johns Hopkins University.

Dr. Clarke joined the company in 2004 and was promoted to the company’s Chief Scientific Officer in 2011. As CSO and Vice President of Research and Development, Dr. Clarke oversees the research efforts dedicated to understanding the impact of Pulmatrix technologies in respiratory disease. As one of the company’s initial scientists, Dr. Clarke was involved in the early stage growth of research and development programs that identified some of the key aspects of the Pulmatrix technology. Previous to Pulmatrix, he was an Associate Director of Life Sciences at Alkermes, Inc. Dr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University, has his Ph.D. in Physiology from Johns Hopkins University, and completed his post-doctoral training in Respiratory Biology at Harvard University. Dr. Clarke has co-authored over 80 chapters, papers, and abstracts focused on pulmonary drug delivery and the role of particles and infection in the lung.

Mr. Welna has over 30 years of high tech financial experience in both biotech and software. Prior to joining Pulmatrix in 2008, Welna was Senior Director, Finance and Operations for Domantis Ltd. Welna joined Domantis in 2002 and was responsible for the development of the financial function for both the UK and U.S. operations, until Domantis was acquired in 2007 by Glaxo SmithKline for $454 million. Prior to Domantis, Welna held various senior level financial positions at Lodestar Corporation, iKnowledge, Inc., and Cayenne Software, Inc. Welna’s extensive background includes experience with mergers and acquisitions, SEC reporting, and international financial management as well as being a Certified Public Accountant (inactive) in Oregon.